Angiotech's resorbable sutures:
This article was originally published in Clinica
Angiotech Pharmaceuticals has received 510(k) clearance from the US FDA for its resorbable sutures product line - Quill SRS Monoderm. The products, part of the company's larger "Quill" range of self-retaining system (SRS) sutures, are made from a rapidly absorbing polymer, and are indicated for use primarily in superficial wound closure. The Vancouver, Canada firm hopes to launch the product line in the US this autumn. The Quill SRS range of sutures incorporates a patented helical barbed design which obviates the need to tie knots to hold sutures in place. Angiotech also gained 510(k) clearance to market additional diameters of its Quill SRS Polydioxanone (PDO) product line - longer-lasting absorbable sutures typically used for deeper tissue closure.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.